Treatment approach to connective tissue disease-associated interstitial lung disease

Timothy M Wilson; Joshua J Solomon; M Kristen Demoruelle

doi:10.1016/j.coph.2022.102245

Treatment approach to connective tissue disease-associated interstitial lung disease

Curr Opin Pharmacol. 2022 Aug:65:102245. doi: 10.1016/j.coph.2022.102245. Epub 2022 Jun 1.

Authors

Timothy M Wilson¹, Joshua J Solomon², M Kristen Demoruelle³

Affiliations

¹ University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA. Electronic address: [email protected].
² National Jewish Health, Division of Pulmonary, Critical Care and Sleep Medicine, Denver, CO, USA.
³ University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA.

Abstract

Interstitial lung disease (ILD) is a common manifestation in connective tissue diseases (CTD), such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myositis (IM). ILD is associated with significant morbidity and mortality in nearly all CTD highlighting the critical need for effective treatment strategies in this patient population. In this review, we will summarize the approach to treatment when there is concern for CTD-ILD and highlight recent advancements in therapeutics within various forms of CTD-ILD.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Arthritis, Rheumatoid*
Connective Tissue Diseases* / complications
Connective Tissue Diseases* / drug therapy
Humans
Lung Diseases, Interstitial* / complications
Lung Diseases, Interstitial* / etiology
Treatment Outcome

Abstract

Publication types

MeSH terms

Grants and funding